Attention Deficit Hyperactivity Disorder Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Attention Deficit Hyperactivity Disorder Market Report is Segmented by Drug Type (Stimulant and Non-Stimulant), Age Group (Children (≤17 Years) and Adults (≥18 Years)), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Attention Deficit Hyperactivity Disorder Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Attention Deficit Hyperactivity Disorder Market with other markets in Healthcare Industry

Attention Deficit Hyperactivity Disorder Market Analysis by Mordor Intelligence

The attention deficit hyperactivity disorder market was valued at USD 17.60 billion in 2025 and is forecast to reach USD 23.03 billion by 2030, advancing at a 5.53% CAGR. Higher diagnostic vigilance, broader adult recognition, and steady innovation in both stimulant and non-stimulant regimens are expanding treatment volumes. Stimulants still anchor most prescriptions, yet non-stimulants gain momentum as physicians seek options with lower abuse potential. Telehealth services now link specialists to underserved communities, compressing wait times for evaluation and prescription fulfilment. North America holds a 42.45% revenue lead thanks to mature reimbursement systems, whereas Asia-Pacific posts the quickest regional climb at 6.54% CAGR, reflecting rising awareness and policy reform.

Key Report Takeaways

  • By drug type, stimulants led with 68.54% of Attention Deficit Hyperactivity Disorder market share in 2024, while non-stimulants are projected to register a 7.45% CAGR to 2030.
  • By age group, the pediatric cohort captured 65.45% revenue in 2024; the adult segment is set to expand at an 8.23% CAGR through 2030.
  • By distribution channel, retail pharmacies held 54.78% of the Attention Deficit Hyperactivity Disorder market size in 2024; online pharmacies are forecast to grow at an 8.65% CAGR to 2030.
  • By region, North America accounted for 42.45% of 2024 revenue; Asia-Pacific is poised for the fastest 6.54% CAGR by 2030.

Segment Analysis

By Drug Type: Non-Stimulants Gain Momentum Despite Stimulant Dominance

Stimulant products generated 68.54% of 2024 revenue, illustrating entrenched efficacy and prescriber familiarity. Yet non-stimulants logged a 7.45% CAGR, exceeding total attention deficit hyperactivity disorder market growth as safety-minded clinicians search for lower diversion risk. Lisdexamfetamine’s patent expiry in 2024 unlocked generic competition; Granules India and Lupin secured FDA approvals, supplying cost-sensitive buyers. DEA production caps pressured amphetamine supply, nudging prescribers toward alternatives such as viloxazine and guanfacine.

Supernus Pharmaceuticals reported Qelbree sales of USD 241.3 million in 2024, a 72% jump year-on-year, signalling robust uptake of novel non-stimulant mechanisms. Atomoxetine use remained steady despite batch recalls elsewhere, underlining persistent need for once-daily options. Liquid clonidine (Onyda XR) now offers paediatric caregivers a nocturnal regimen that circumvents school-time dosing hurdles. Consequently, the attention deficit hyperactivity disorder market size for non-stimulants is forecast to expand faster than any subcategory through 2030.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Age Group: Adult Recognition Drives Expansion

Paediatric patients accounted for 65.45% of diagnoses in 2024, but adult cases are rising at an 8.23% CAGR. Many adults long mislabelled as “underachieving” now secure formal evaluations, buoyed by professional society guidelines and workplace accommodation policies. Japanese cohort work revealed mood-disorder comorbidity in 60.9% of affected adults, necessitating integrated care[3]Frontiers in Psychiatry, “Comorbidities in Adult ADHD,” frontiersin.org. Telehealth proves pivotal: 67.2% of virtual users procured ADHD medications online in 2024, an access vector especially valuable for rural communities.

The attention deficit hyperactivity disorder market size attributable to adult therapies is projected to eclipse USD 11 billion by 2030, propelled by format innovations such as CTx-1301 that address eight-hour workdays without midday boosters. Paediatric care is evolving too: behaviour first for under-6s, pharmacotherapy for school-age children when educational performance falters. The CDC counted 2 million untreated U.S. children with ADHD in 2022, highlighting residual opportunity. Holistic family-centred programs now pair parent training with medication, reinforcing adherence and academic gains.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Distribution Channel: Digital Transformation Accelerates Online Growth

Retail chains remained the prime outlet with 54.78% market share, backed by insurance integration and pharmacist counselling. Still, online pharmacies post the quickest 8.65% CAGR, spurred by same-day delivery and easier shop-around during shortages. Integrated e-prescription systems now auto-route telehealth orders to mail-order fulfilment, shrinking friction. Hospital pharmacies uphold initiation for complex comorbid cases but hold a stable share given outpatient dominance of ADHD treatment.

Specialty pharmacies carve a niche for high-cost or liquid formulations requiring temperature control and adherence coaching. DEA proposals for in-person exams before remote refills loom as a wildcard that could temper online traction. Retail players retaliate by embedding screeners and nurse-led consults in-store, forging a hybrid model. Consequently, the attention deficit hyperactivity disorder market is likely to see blurred channel boundaries rather than a zero-sum shift.

Geography Analysis

North America, with 42.45% 2024 revenue, remains the anchoring geography. In 2023, U.S. pharmacies dispensed 45 million stimulant prescriptions, up from 35.5 million in 2019, indicating pervasive clinical adoption. Canada’s claim volumes climbed 20% in 2024 after provinces widened coverage, reinforcing access. Regional innovation depth is notable: most first-in-class approvals—Onyda XR, solriamfetol, CTx-1301—originated or were trialled here, underscoring a pipeline advantage.

Europe offers a structurally mature but controlled environment. Post-pandemic, prescription volumes ran 16.4% above pre-COVID forecasts by 2022, signalling greater societal comfort with pharmacologic care. The EMA’s green lights for Paxneury and Tuzulby added guanfacine and extended-release methylphenidate choices to paediatric algorithms. Germany spearheads digital therapeutics; EndeavorRx secured CE marking and a reimbursement code, accelerating adoption pathways.

Asia-Pacific delivers the fastest 6.54% CAGR, lifted by policy liberalisation and urbanising populations. Japan’s government-backed biotech incentives catalyse neuroscience start-ups, widening clinical trial capacity. China’s 6.4% paediatric prevalence equates to tens of millions of potential patients as screening scales nationally. India’s manufacturers leverage FDA approvals—such as generic Vyvanse—to supply lower-priced options globally, reinforcing regional affordability. Remaining hurdles include rural service gaps and persisting stigma, but rising digital literacy mitigates some obstacles, suggesting the attention deficit hyperactivity disorder market will experience steady diffusion across megacities first, then into secondary centres.

Attention Deficit Hyperactivity Disorder Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Consolidation meets disruption. Takeda’s Vyvanse patent lapse prompted a USD 900 million restructuring after profit slid 57%, illustrating post-exclusivity pressure. Collegium’s USD 525 million buyout of Ironshore Therapeutics gave it Jornay PM, signalling diversification beyond pain franchises. Supernus’s viloxazine success proves that differentiated non-stimulants can flourish even in a stimulant-heavy arena.

Digital entrants reshape therapeutic hierarchies. EndeavorRx, cleared for paediatric use, obviates controlled-substance protocols and is now reimbursed by multiple U.S. payers. Cingulate’s timed-release approach targets adherence pain points unaddressed by incumbents. Supply volatility also creates openings; companies with robust manufacturing capacity or alternative mechanisms can capture prescriptions when quota-bound competitors run short. Net effect: the attention deficit hyperactivity disorder market exhibits moderate concentration, with roughly 60% of revenue held by the five leading firms, yet ongoing innovation keeps competitive intensity high.

Attention Deficit Hyperactivity Disorder Industry Leaders

  1. Takeda Pharmaceutical Co.

  2. Novartis AG

  3. Johnson & Johnson (Janssen)

  4. Eli Lilly & Co.

  5. Pfizer Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Attention Deficit Hyperactivity Disorder Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • May 2025: Cingulate completed Phase 3 safety testing for CTx-1301 and scheduled an NDA submission for mid-2025.
  • March 2025: Axsome Therapeutics’ solriamfetol met Phase 3 endpoints in adult ADHD, achieving a 45% mean symptom reduction.
  • February 2025: Supernus Pharmaceuticals confirmed 72% Qelbree sales growth to USD 241.3 million for 2024, aided by a label update highlighting low breast-milk transfer.
  • January 2025: Johnson & Johnson announced a USD 14.6 billion agreement to acquire Intra-Cellular Therapies, adding CAPLYTA to its neuroscience stable with future ADHD indications possible.
  • January 2025: Granules India gained FDA clearance for generic lisdexamfetamine dimesylate, expanding its ADHD product range.

Table of Contents for Attention Deficit Hyperactivity Disorder Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising ADHD Prevalence Worldwide
    • 4.2.2 Growing Awareness and Screening Initiatives
    • 4.2.3 Advancements in Pharmacotherapy and Formulations
    • 4.2.4 Supportive Reimbursement and Coverage Policies
    • 4.2.5 Expanding Adult Patient Segment Via Telehealth
    • 4.2.6 Integration of Digital Therapeutics with Medication
  • 4.3 Market Restraints
    • 4.3.1 Diagnostic Challenges and Underrecognition
    • 4.3.2 High Abuse Liability and Safety Concerns of Stimulants
    • 4.3.3 Strict Regulatory Controls on Controlled Substances
    • 4.3.4 Cost Containment Pressures from Healthcare Payers
  • 4.4 Regulatory Landscape
  • 4.5 Porter's Five Forces Analysis
    • 4.5.1 Threat Of New Entrants
    • 4.5.2 Bargaining Power Of Buyers
    • 4.5.3 Bargaining Power Of Suppliers
    • 4.5.4 Threat Of Substitutes
    • 4.5.5 Competitive Rivalry Intensity

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Drug Type
    • 5.1.1 Stimulant
    • 5.1.1.1 Amphetamine
    • 5.1.1.2 Methylphenidate
    • 5.1.1.3 Dextroamphetamine
    • 5.1.1.4 Dexmethylphenidate
    • 5.1.1.5 Lisdexamfetamine Dimesylate
    • 5.1.2 Non-Stimulant
    • 5.1.2.1 Atomoxetine
    • 5.1.2.2 Bupropion
    • 5.1.2.3 Guanfacine
    • 5.1.2.4 Clonidine
  • 5.2 By Age Group
    • 5.2.1 Children (<17 Years)
    • 5.2.2 Adults (>18 Years)
  • 5.3 By Distribution Channel
    • 5.3.1 Retail Pharmacy
    • 5.3.2 Hospital Pharmacy
    • 5.3.3 Online Pharmacy
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
    • 6.3.1 Takeda Pharmaceutical Co. (Shire)
    • 6.3.2 Novartis AG
    • 6.3.3 Johnson & Johnson (Janssen)
    • 6.3.4 Eli Lilly & Co.
    • 6.3.5 Pfizer Inc.
    • 6.3.6 Mallinckrodt plc
    • 6.3.7 Supernus Pharmaceuticals
    • 6.3.8 Aytu BioPharma (NEOS Therapeutics)
    • 6.3.9 Ironshore Pharmaceuticals
    • 6.3.10 KemPharm Inc. (Corium)
    • 6.3.11 Tris Pharma
    • 6.3.12 Aurobindo Pharma
    • 6.3.13 Lupin Ltd.
    • 6.3.14 Otsuka Holdings
    • 6.3.15 Hisamitsu Pharma (Noven)
    • 6.3.16 Purdue Pharma (Adlon)
    • 6.3.17 Corium Inc.
    • 6.3.18 Sun Pharmaceutical Inds.
    • 6.3.19 Amneal Pharmaceuticals
    • 6.3.20 H. Lundbeck A/S
    • 6.3.21 Shionogi & Co. Ltd.
    • 6.3.22 Rhodes Pharmaceuticals

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Attention Deficit Hyperactivity Disorder Market Report Scope

As per the scope of the report, Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders that primarily affects children. ADHD is often diagnosed in childhood and persists into adulthood. Children with ADHD may daydream excessively, forget or lose things, have difficulty resisting temptation, have trouble taking turns, have difficulty getting along with others, be overly active, and have difficulty paying attention. The attention deficit hyperactivity disorder market is segmented by drug type (stimulant, non-stimulant), age (adult (aged 18 and above), children), distribution (retail pharmacy, hospital pharmacy), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Drug Type Stimulant Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine Dimesylate
Non-Stimulant Atomoxetine
Bupropion
Guanfacine
Clonidine
By Age Group Children (<17 Years)
Adults (>18 Years)
By Distribution Channel Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Drug Type
Stimulant Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine Dimesylate
Non-Stimulant Atomoxetine
Bupropion
Guanfacine
Clonidine
By Age Group
Children (<17 Years)
Adults (>18 Years)
By Distribution Channel
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the projected size of the Attention Deficit Hyperactivity Disorder market by 2030?

The Attention Deficit Hyperactivity Disorder market is expected to reach USD 23.03 billion by 2030, expanding at a 5.53% CAGR.

Which drug class dominates current sales?

Stimulant medications held 68.54% of the Attention Deficit Hyperactivity Disorder market share in 2024, supported by long-standing efficacy data.

Why are non-stimulants gaining popularity?

Prescribers and patients seek alternatives with lower abuse risk, and new agents like viloxazine show strong efficacy and growth, posting a 7.45% CAGR forecast.

How fast is the adult segment growing?

Adult diagnoses are rising at an 8.23% CAGR as telehealth makes specialist evaluation more accessible and guidelines formalise adult screening.

Which region offers the highest growth potential?

Asia-Pacific leads with a 6.54% forecast CAGR thanks to improving awareness, favourable policy shifts, and expanding healthcare infrastructure.

How are digital therapeutics impacting treatment?

FDA-cleared platforms such as EndeavorRx provide non-pharmacologic options, alleviating supply constraints and safety concerns tied to controlled stimulants.

Attention Deficit Hyperactivity Disorder Market Report Snapshots